Drug Database
RH

rhIFN-alpha (ReliFeron)

✓ Approved

Reliance Life Sciences Private Limited · IFNAR2 · Recombinant Proteins

What is rhIFN-alpha?

rhIFN-alpha is a recombinant proteins developed by Reliance Life Sciences Private Limited. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesReliFeron
CompanyReliance Life Sciences Private Limited
Drug ClassRecombinant Proteins
Molecular TargetIFNAR2
RouteInjectable (Others), Intramuscular (IM) Injection, Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Reliance Life Sciences Private Limited

Mechanism of Action

Molecular Targets

rhIFN-alpha acts on 1 molecular target:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

rhIFN-alpha is developed for 8 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-Hodgkin's lymphoma✓ Approved

+3 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedOral health & preventive dentistry2026-11-11

Validation of the Turkish Oral Health Impact Profile-17 for Assessing Oral Health-Related Quality of Life in Endodontic Patients.

Çetinkaya Oğuz Burhan OB, Gözübüyük Betül Banu BB, Yüksekkaya İrfan İ, Gündoğar Hasan H

To evaluate the reliability and construct validity of the Turkish version of the Oral Health Impact Profile-17 (OHIP-17-TR) in patients receiving endodontic treatment. This methodological, cross-sectional validation study included 229 adult patients undergoing or having recently completed endodontic treatment. Participants completed the OHIP-17-TR questionnaire. Internal consistency was assessed using Cronbach alpha and corrected item-total correlations. Construct validity was evaluated through exploratory factor analysis (EFA). Sampling adequacy was examined using the Kaiser-Meyer-Olkin (KMO) measure and Bartlett test of sphericity. Test-retest reliability was not assessed. The OHIP-17-TR showed high internal consistency, with a Cronbach alpha of 0.894. Corrected item-total correlations ranged from 0.345 to 0.675. The KMO value was 0.882, and the Bartlett test was significant (P 0.001), indicating suitability for factor analysis. Exploratory factor analysis identified a four-factor structure explaining 51.8% of the total variance, with all items demonstrating salient factor loadings. Subscale Cronbach alpha values ranged from 0.689 to 0.862. The OHIP-17-TR demonstrated good reliability and acceptable construct validity in this sample of endodontic patients. These findings support the use of OHIP-17-TR as a brief and practical patient-reported outcome measure for assessing oral health-related quality of life in endodontic research and clinical practice.

PMID 43012462
Read full article →
PubMedMedicine2026-11-11

Association between alpha-fetoprotein elevation and recurrence in patients who achieved normalized alpha-fetoprotein after curative resection for hepatocellular carcinoma: A retrospective cohort study.

Hwang Jeong Ah JA, Lee Jisun J, Yi Kyung Sik KS, Choi Chi-Hoon CH et al.

Alpha-fetoprotein (AFP) is a cornerstone biomarker for hepatocellular carcinoma (HCC) surveillance following curative resection. Although AFP normalization generally indicates effective tumor control, subsequent AFP elevation poses a diagnostic dilemma due to its potential association with both tumor recurrence and nonneoplastic liver conditions. This study aimed to determine the factors influencing AFP elevation and to assess the role of serial AFP testing for the early detection of recurrent HCC, thereby addressing an unmet need in refining postoperative surveillance strategies. In this retrospective cohort study, 705 patients who underwent curative resection for HCC between January 2018 and March 2020 and achieved AFP normalization were analyzed. Postoperative surveillance included AFP and imaging exams, with AFP elevation defined as ≥ 20 ng/mL and normalization as AFP < 20 ng/mL post-surgery. Multivariable analysis identified factors associated with AFP elevation. Recurrence occurred in 34.6%. Independent factors associated with AFP elevation included recurrence (odds ratio [OR] = 21.9; 95% confidence interval [CI] = 7.5-64.2), preoperative AFP elevation (OR = 3.6; 95% CI = 1.7-7.6), logAFP at normalization (OR = 12.7; 95% CI = 3.5-45.7), and cirrhosis (OR = 2.2; 95% CI = 1.0-4.5). In patients without recurrence, logAFP at normalization (OR = 12.6; 95% CI = 3.7-43.4) and cirrhosis (OR = 2.2; 95% CI = 1.1-4.5) were independently associated with false positive elevation. Intrahepatic recurrence accounted for 69.2%, with lesions of ≤ 1 cm composing 88.9%. Following a preceding AFP elevation, recurrence was detected after a median of 4.8 months and within 12 months in all cases. AFP elevation during postoperative surveillance is a strong indicator of HCC recurrence. In cases where AFP elevation occurs without clear radiologic evidence of recurrence, early and frequent liver MRI (at intervals of ≤ 3 months for at least 12 months) is recommended to facilitate prompt detection of intrahepatic lesions. Moreover, clinicians should be mindful that elevated normalized AFP levels and underlying cirrhosis increase the risk of false positive elevations. These findings underscore the need for a tailored surveillance strategy to optimize the early diagnosis and management of recurrent HCC.

PMID 43012784
Read full article →
PubMedMRS bulletin2026-11-11

Electron probe microanalysis as a versatile tool to probe the chemistry of radioactive wasteforms.

Creasey-Gray Stuart S, Stennett Martin M, Thorpe Clare C, Manifold Garry G et al.

Electron probe microanalysis (EPMA) is a powerful, nondestructive microscopy tool that finds ubiquitous application in the broader field of materials science. Herein, it was demonstrated that EPMA is a versatile tool for probing the chemistry of nuclear materials, particularly wasteform systems for the immobilization of intermediate and high-level radioactive waste, with constituents such as Cs, Sr, U and Pu. This communication evidences the efficacy of EPMA to further understand the five distinct wasteform systems for both nonradioactive surrogate material particularly relevant to the UK radioactive waste management and disposal program, including alpha-active systems containing 238U.

PMID 43011317
Read full article →
PubMedFrontiers in pharmacology2026-11-11

Cost-effectiveness of inavolisib plus palbociclib/fulvestrant versus palbociclib/fulvestrant for PIK3CA-mutated advanced breast cancer in China.

Xiang Zuojuan Z, Chen Xiaojuan X, Ma Ling L

Based on the positive findings of the INAVO120 study, inavolisib is the only phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor approved for breast cancer treatment in China and has been included in the National Reimbursement Drug List following national medical insurance price negotiations. A partitioned survival model with a 30-year time horizon was constructed to assess the cost-effectiveness of inavolisib plus palbociclib/fulvestrant versus palbociclib/fulvestrant alone in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, hormone receptor (HR)+, human epidermal growth factor receptor 2 (HER2)-, locally advanced or metastatic breast cancer (a/m BC). Clinical data were extracted from the Asian cohort of the INAVO120 trial. Drug prices were sourced from the government procurement platform, while additional cost and utility parameters were derived from the published literature. The primary model outcome was the incremental cost-effectiveness ratio (ICER). To assess the robustness of the results, scenario and sensitivity analyses were performed. Additionally, a price simulation analysis was conducted for inavolisib. The ICER was determined to be $36,932.91/quality-adjusted life-year (QALY), which exceeded the willingness-to-pay (WTP) threshold of $27,906/QALY. To attain cost-effectiveness, a further price reduction of 27.02% for inavolisib would be necessary. Scenario and sensitivity analyses confirmed the robustness of the results. The addition of inavolisib to palbociclib plus fulvestrant for PIK3CA-mutated HR+/HER2-a/m BC is not a cost-effective treatment strategy at the national level in China. However, this triple therapy may achieve cost-effectiveness in economically affluent regions with higher local WTP thresholds.

PMID 43011102
Read full article →
PubMedRSC medicinal chemistry2026-11-11

Expanding the chemical space of guanidinium-stapled peptides with aromatic residues yields NCOA mimics with high affinity for nuclear receptors.

Trousselier Pauline P, Silvestri Aurora A, Peluso-Iltis Carole C, Osz Judit J et al.

Macrocyclization via guanidinium stapling is a modular synthetic approach to stabilize α-helical peptides and create constrained arginine mimics, while introducing positively charged, hydrogen-bonding moieties. To expand the structural diversity of guanidinium-stapled peptides, we incorporated non-natural amino acids, p-azidomethyl-l-phenylalanine (F*) and O-(2-azidoethyl)-l-tyrosine (Y*), to introduce aromatic groups into the macrocycle. We demonstrate compatibility with (i, i + 4) and (i, i + 7) stapling geometries and apply this approach to mimic nuclear receptor coactivator (NCOA) peptides for binding to human nuclear hormone receptors (NHR), including retinoic acid receptor alpha (RARα) and vitamin D receptor (VDR). Our structural and biophysical analyses reveal that aromatic elements within the guanidinium staple can modulate helical stability, enhance binding affinity, and contribute direct interactions with the protein surface.

PMID 43011727
Read full article →
PubMedJournal of perioperative practice2026-11-11

Perianaesthetic comfort in patients undergoing day-case biopsy surgery: A pilot feasibility study.

Akbal Sevim S, Gökçe Işıklı Ayşe A, Önüt Fatma F

Day-case biopsy surgery combines procedural stress with diagnostic uncertainty. This pilot feasibility study aimed to describe perianaesthetic comfort, identify associated factors, and assess the Perianaesthetic Comfort Scale (PCS) in this setting. A descriptive, cross-sectional census over one year in one Turkish university day-surgery unit recruited 46 of 50 eligible patients (92%). Mean age was 55.1 (SD 14.4) years; 60.9% were male. Mean total PCS score was 117.9 (SD 10.2; range 90-134; possible range 24-144). Scores were lower with chronic comorbidity (115.4, SD 10.5) than without (121.0, SD 9.1; U = 364, p = 0.025, r = 0.33, power 64%). No associations were found with age, gender, education, prior surgery, anaesthesia mode, fasting or anaesthesia duration, or pain. Internal consistency was low (Cronbach's alpha 0.65). These preliminary findings suggest chronic comorbidity may reduce perianaesthetic comfort; the PCS requires further psychometric evaluation before use in day-case biopsy populations.

PMID 43012153
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rhIFN-alpha